Sep 2026· The Prostate· Vol 86, pp. 1590-1603· 0 citations· 26 references
Medicine
TL;DR
This prospective single-center study examined whether prostate-specific antigen (PSA)-based measures could identify a low-risk subgroup suitable for biopsy deferral in patients with Prostate Imaging-Reporting and Data System (PI-RADS) 1-3 lesions, and which clinical & imaging factors further refined risk stratification.
Abstract
Background
Management of men with equivocal MRI findings remains uncertain, while low-risk MRI may still harbor clinically significant prostate cancer (csPCa). We examined whether prostate-specific antigen (PSA)-based measures could identify a low-risk subgroup suitable for biopsy deferral in patients with Prostate Imaging-Reporting and Data System (PI-RADS) 1-3 lesions, and which clinical & imaging factors further refined risk stratification.
Methods
This prospective single-center study included 473 consecutive patients with index PI-RADS 1-3 findings on prostate MRI who underwent systematic and/or MRI/US fusion-guided biopsy between May 2019 and December 2025. Patient-level csPCa (grade group ≥ 2) detection rates (CDR) were calculated across PI-RADS groups. csPCa detection, biopsy avoidance, and missed csPCa were assessed using biopsy-deferral thresholds based on PSA (< 3 ng/mL), age-adjusted PSA, and PSA density (PSAD) (< 0.10 and < 0.15 ng/mL2). Logistic regression analyses identified independent predictors of PCa and csPCa.
Results
The cohort comprised 172 patients with PI-RADS 1, 126 with PI-RADS 2, and 175 with PI-RADS 3 index lesions. In PI-RADS 1-2, csPCa was detected in 2.2% (1/46) of patients with PSA < 3, whereas for PSAD < 0.10, the CDR was 5.3% (10/190). Avoided biopsy rates were 15.4% (46/298) and 63.8% (190/298), and missed csPCa rates were 3.3% (1/30) for PSA < 3% and 33.3% (10/30) for PSAD < 0.10, respectively. In PI-RADS 1-3, csPCa was detected in 5.6% (4/76) of patients with PSA < 3 ng/mL, while for PSAD < 0.10, CDR was 8.8% (26/295). Biopsy avoidance was 16.1% (76/473) for PSA < 3 ng/mL and 62.4% (295/473) for PSAD < 0.10, with missed csPCa rates of 5.6% (4/71) and 36.6% (26/71), respectively. On multivariable analysis, higher log2(PSAD) was independently associated with csPCa in both PI-RADS 1-2 (OR, 2.171; 95% CI, 1.255-3.757; p = 0.006) and PI-RADS 1-3 (OR, 2.727; 95% CI, 1.844-4.033; p < 0.001) cohorts. In patients with index PI-RADS 1-3 findings, prior negative biopsy was independently associated with lower odds of csPCa (OR = 0.425; 95% CI, 0.182-0.991; p = 0.048). Non-diagnostic MRI quality was independently associated with PCa detection in the PI-RADS 1-2 cohort (OR, 2.367; 95% CI, 1.276-4.388; p = 0.006).
Conclusions
In men with index PI-RADS 1-3 lesions, PSA < 3 ng/mL identified a very low-risk subgroup with low csPCa detection, and few missed csPCa. Conventional PSAD cutoffs performed worse for biopsy deferral, with a higher rate of missed csPCa. Biopsy decisions for PI-RADS 1-3 lesions are best guided by a composite assessment that incorporates PSA, PSAD, PI-RADS category, prior biopsy status, MRI quality, and lesion burden.
Magnetic resonance imaging (MRI) before biopsy has replaced systematic transrectal ultrasound-guided sampling as the first diagnostic step for men with suspected prostate cancer; the open question is which men can safely forgo biopsy after imaging. This narrative review synthesised randomised trials, paired diagnostic...
Alaa Menshawy, R. Elmassry· Clinical Standard· 0 citations
BACKGROUND
Prostate Imaging Reporting and Data System (PI-RADS) 3 lesions often undergo biopsy despite a low positive predictive value (< 25%) for clinically significant prostate cancer (csPCa), defined as International Society of Urological Pathology (ISUP) Grade Group ≥ 2.
PURPOSE
To determine whether mean apparent...
Tejinder Kaur, R. Chahine, N. Seiberlich et al.· Journal of Magnetic Resonanc...· 0 citations
Prostate Imaging Reporting and Data System (PI-RADS) 3 lesions on multiparametric magnetic resonance imaging (mpMRI) represent an equivocal category with an uncertain risk of clinically significant prostate cancer (csPCa), resulting in persistent controversy regarding biopsy indications. Our objective was to evalua...
W. Połom, K. Skrobisz, Anna Połom-Czepek et al.· Polish Journal of Radiology· 0 citations
To evaluate whether restricting systematic biopsy to the ipsilateral side of a unilateral multiparametric magnetic resonance imaging (mpMRI) lesion, in combination with cognitive MRI-targeted biopsy, affects the detection of clinically significant prostate cancer (csPCa) in biopsy-naïve patients.
This retr...
G. Tsakaldimis, D. Diamantidis, Nikolaos Smyrlis et al.· BMC Urology· 0 citations
BACKGROUND
Management after suspicious multiparametric MRI (mpMRI; PI-RADS ≥ 3) and an initial biopsy negative for clinically significant prostate cancer (csPCa) remains uncertain. We described the frequency of subsequent csPCa detection and explored baseline factors.
METHODS
This post hoc longitudinal analysis of MU...
Wafa D. Aloufi, M. Szewczyk-Bieda, Ghulam Nabi et al.· The Prostate· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.